Jul 21, 2022 / 01:30PM GMT
Operator
Good day, and welcome to the Sartorius and Sartorius Stedim Biotech conference call on the H1 2022 results. Today's conference is being recorded.
At this time, I would like to turn the conference over to Dr. Joachim Kreuzburg, CEO. Please go ahead, sir.
Joachim Kreuzburg - Sartorius Aktiengesellschaft - Chairman of Executive Board & CEO
Thank you very much and also good afternoon and good morning from my side, and welcome to our H1 conference call. I would like to start walking you through the highlights of the first half year 2022 of the Sartorius Group and then hand over to Rainer for the details on the Sartorius Group's numbers to take over then commenting on the guidance for the full year and also walking you through the SSB numbers.
So look on the highlights now. We have achieved double-digit growth of sales revenue in both divisions. The same is for the underlying EBITDA, so the profitability margins remain at the same high levels. And that is despite the inflationary trends that we are seeing as well as headwinds from FX, more
Q2 2022 Sartorius AG Earnings Call Transcript
Feb 14, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers